YahooOctober 26, 2026 at 8:04 PM NY19 Hours Ago
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts
Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab tirumotecan, or sac-TMT, antibody-drug conjugate in endometrial cancer and its individualized neoantigen t
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
